Aviceda Therapeutics winds down after Phase 2 failure

· Health

Aviceda Therapeutics, a biotech that planned to take an eye drug into Phase 3 this year despite a mid-stage setback, is winding down, according to a source familiar with the decision.

Why it matters：The wind-down of a single-asset biotech after a mid-stage failure underscores the risks in drug development.

Key points

  • The drug targeted geographic atrophy.
  • The company had planned to start Phase 3 this year.
  • The decision follows a Phase 2 failure.

Sources (original reporting)

More stories from this day